TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03173638

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intravitreal injection of MSV
Description: A unique intravitreal injection of MSV in acute fase of NAION
Study: NCT00556400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lo-Ovral Oral Contraceptive Pills

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - sugar pill
Study: NCT02552056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAMH training
Description: Training of PHC workers included in the study for 5 days to screen children and adolescents for CAMH conditions, based in the mhGAP curriculum for non-specialist health providers.
Study: NCT03376230

Intervention type: OTHER
Intervention: Collect of blood, urines, and intestinal biopsies

Intervention type: OTHER
Intervention: Collect of blood, urines, and intestinal biopsies

Intervention type: OTHER
Intervention: Collect of blood, urines, and intestinal biopsies
Study: NCT02422771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIFA 11+ warm-up
Description: A sequence of 15 exercises performed before soccer practices and games. The exercises include strength, agility, balance and motor control components and take about 15-20 minutes to perform. The intervention replaces any previous warm-up the athletes may have done.
Study: NCT01133886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Patients will receive decitabine as a 20mg/m2 one hour intravenous infusion once daily on days 1 to 5 of a 4 week cycle.
Study: NCT02229123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Levetiracetam
Description: Open-study. If seizure lasting more than 3 minutes on EEG recording or brief repeated seizures (more or equal to 2 seizures lasting more than 20 seconds on a 1 hour-interval), the loading-dose of LEV allocated to patient is infused followed by the 8 maintenance dose.
Study: NCT03449550

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Respiratory Polygraphy (HRP)
Description: Randomizing to start with home respiratory polygraphy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Polysomnography (PSG)
Description: Randomizing to start with Standard Polysomnography (PSG)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Respiratory Polygraphy (HRP)
Description: Randomizing for therapeutic decision taken with home respiratory polygraphy (HRP)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Polysomnography (PSG)
Description: Randomizing for therapeutic decision taken with Standard Polysomnography (PSG)
Study: NCT02967796

Intervention type: DIETARY_SUPPLEMENT
Intervention: Proteochoc
Study: NCT02798744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Daily energy restriction diet to be followed for the duration of the study (24 weeks)
Study: NCT03091426

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle
Study: NCT05067712

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Surgical Exposure Technique
Description: * A mucoperiosteal palatal flap is elevated off the bone from the premolar to the midline~* The bone covering the crown aspect of the canine is removed until the largest diameter of the crown is exposed~* Follicular tissue is removed from the exposed crown area~* The flap is repositioned back and sutured~* The area over the exposed canine crown is excised leaving a window with the crown uncovered.~* If the tooth is deeply embedded in the bone, a dressing is placed over the uncovered crown and kept in place with sutures.~* The extraction of the primary canine (if present) is made before or in connection with the surgical exposure.~* Ten to fifteen days later the dressing and sutures are removed and the tooth is left to erupt autonomously.~* When the canine has spontaneously erupted above the palatal mucosa an attachment is bonded to the crown and the canine is moved into alignment in the dental arch above the mucosa with orthodontic appliances.
Study: NCT02798744

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Daily energy restriction diet to be followed for the duration of the study (24 weeks)
Study: NCT05067712

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed Surgical Exposure Technique
Description: * A mucoperiosteal palatal flap is elevated off the bone from the premolar to the midline~* The bone covering the crown aspect of the canine is removed until the largest diameter of the crown is exposed.~* Follicular tissue is removed from the exposed crown area.~* An attachment with a chain is bonded to the exposed canine crown.~* The flap is repositioned back and sutured to cover the exposed crown leaving the chain through the palatal mucosa free in the oral cavity~* The extraction of the primary canine (if present) made before or in connection with the surgical exposure~* Ten to fifteen days later the sutures are removed.~* Within days, traction is applied to the canine with orthodontic appliances by means of the chain, and the canine is pulled through the palatal mucosa out to the oral cavity and into alignment in the dental arch.
Study: NCT02798744

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for the duration of the study (24 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for the duration of the study (24 weeks)
Study: NCT03818906

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Molar extraction - Control Group
Description: The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.
Study: NCT04325685

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Oropharyngeal decontamination with saline will be performing three time a day every 8 hours during mechanical ventilation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiseptic Solution
Description: Oropharyngeal decontamination with antiseptic solution will be performing three time a day every 8 hours during mechanical ventilation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacteriophage
Description: Oropharyngeal decontamination with bacteriophage will be performing three time a day every 8 hours during mechanical ventilation
Study: NCT06522178

Intervention type: OTHER
Intervention: Patient' ages
Description: Patients were divided into two groups according to their ages.

Intervention type: OTHER
Intervention: Patient' ages
Description: Patients were divided into two groups according to their ages.
Study: NCT03932162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin-Like Growth Factor 1
Description: Growth factor protein
Study: NCT03818906

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aPDT + Molar Extraction - Test Group 1
Description: The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive in their internal portion a local application of aPDT.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infrared + Molar Extraction - Test Group 2
Description: The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive local application of infrared in vestibular external portion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aPDT + Infrared + Molar Extraction - Test Group 3
Description: The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive in their internal portion a local application of aPDT and after that will receive local application of infrared in vestibular external portion.
Study: NCT00325130

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine
Description: Quadrivalent HPV vaccine was provided by the SPONSOR in single-dose vials containing a volume of 0.75 mL. The vaccine was administered as a~0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine
Description: Quadrivalent HPV vaccine was provided by the SPONSOR in single-dose vials containing a volume of 0.75 mL. The vaccine was administered as a~0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Menactra™ (Concomitant)
Description: A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Adacel™ (Concomitant)
Description: a single administration of 0.5 mL intramuscular injection administered in a limb opposite that of quadrivalent HPV injection at Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Menactra™ (Non-concomitant)
Description: A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1
Study: NCT03932162

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Insulin-Lie Growth Factor 1
Description: No Insulin-Like Growth Factor 1 will be given.
Study: NCT02362867

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Balanced Knee System
Description: A multi-compartmental total knee replacement providing a system of components for primary posterior cruciate ligament substituting procedures. The system consists of femoral, tibial, and patellar components that allow the surgeon to select the most appropriate component combination to meet specific patient needs.
Study: NCT02901197

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education and Reminder Posters
Description: See arm description

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Policy Change
Description: See arm description
Study: NCT03041064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50/100
Description: SPF

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100/50
Description: SPF
Study: NCT02245555

Intervention type: DRUG
Intervention: Tamsulosin
Study: NCT03953859

Intervention type: GENETIC
Intervention: double strand break
Description: an induction of a double strand break will be made in the embryos generated for this research and the repair mechanism observed
Study: NCT04749784

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Dose Arterin Cholesterol
Description: 240mg active ingredient daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Dose Arterin Cholesterol
Description: 120mg active ingredient daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT00220038

Intervention type: BEHAVIORAL
Intervention: smell tests
Description: subjects are instructed to sniff two vials, one containing the solvent, the other a dilution of the odorant. They are asked to scan the vial with the stronger odor.
Study: NCT04761536

Intervention type: OTHER
Intervention: Rectal cancer case centralization
Description: In November 2016, the decision to centralize rectal cancer patients to only one surgical unit was taken, with only two surgeons performing the procedures. Furthermore, a close collaboration with local Gastroenterology Units and General Practiotioners was started in order to increase colorectal cancer case referral to our unit. At the same time, we decided to promote the use of laparoscopy and to implement ERAS protocol in our colorectal surgery practice.
Study: NCT05729997

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening to live classical music
Description: The group of musicians perform music in the hemodialysis room while patients receive treatment.
Study: NCT00912600

Intervention type: OTHER
Intervention: Intensive Care Unit admission
Description: Intensive Care Unit admission
Study: NCT01721291

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SALBUTAMOL
Description: In the LUNG DEPOSITION STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT SLOW INHLATION AND AGAIN AT FAST INHALTION;DOSAGE- 30 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION.~In the LUNG PHYSIOLOGY STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT TWO DOSAGES OF 30 MICROGRAMS AND AGAIN AT 15 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION. ALL INHALATIONS WIL BE AT SLOW INHALTION IN THIS PART OF THE STUDY.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SALBUTAMOL
Description: In the LUNG DEPOSITION STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT SLOW INHLATION AND AGAIN AT FAST INHALTION;DOSAGE- 30 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION.~In the LUNG PHYSIOLOGY STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT TWO DOSAGES OF 30 MICROGRAMS AND AGAIN AT 15 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION. ALL INHALATIONS WIL BE AT SLOW INHALTION IN THIS PART OF THE STUDY.
Study: NCT02045056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03186261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nano silver fluoride solution
Description: Nano silver fluoride that composed of silver nanoparticles, chitosan and fluoride that combines preventive and antimicrobial properties.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cavity Cleanser
Description: Moistens dentin surface after cavity preparation using a micro brush.
Study: NCT03581682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-Clinic Visits Using Parent-Acquired Echos
Description: Every patient will have a tele-visit and an on-site clinic visit 1 day apart 3-6 months after the training session. Parents will have a 1-hour hands-on training session to acquire basic echo images on their children with the same hand-held device that they will use during the tele-visit. The parents will also have an in-service on how to take weight, height, and blood pressure measurements, and how to use the digital stethoscope.~A tele-visit will be schedule a day prior to the patient's regularly scheduled clinic visit. Tele-visit elements will include interim medical history by the parent and patient, and weight, height, vital signs, digital cardiac auscultation, and home echo, all obtained by the parent. Two MFS physicians, following our routine MFS care protocol, will administer either the tele-visit or on-site clinic visit, masked to the findings of the other.
Study: NCT00431496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Cinacalcet tablets
Study: NCT04213118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Anlotinib 12mg QD PO d1-14, 21 days per cycle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE first, followed by anlotinib within day4（+/-1days）
Study: NCT03872193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Virtual Reality Exercies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Virtual Reality Exercies
Study: NCT03061812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine
Description: Powder for solution for infusion in vials.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Powder or solution for infusion in vials. Topotecan is commercially available as both a powder and solution for infusion. Availability will vary by region.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablet.
Study: NCT04681924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet intervention
Description: Low carb diet group are compared to low fat diet group and followed up for 6 months
Study: NCT00751907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: 40mg daily for 4 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo daily for 4 months
Study: NCT02140723

Intervention type: RADIATION
Intervention: preoperative short course radiation
Study: NCT05134246

Intervention type: PROCEDURE
Intervention: Carotid endarterectomy (CEA)
Description: Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA and CAS. Patients will receive 100 mg of aspirin or 75 mg of clopidogrel daily starting from at least 72 h prior to the CEA procedure and continued receiving the medication indefinitely. General anesthesia is recommended for CEA, although the use of standard or eversion endarterectomy, and a shunt or patch, is left to the discretion of the surgeon.

Intervention type: PROCEDURE
Intervention: Carotid artery stenting (CAS)
Description: Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA and CAS. Patients will be given 100 mg of aspirin plus 75 mg of clopidogrel daily for at least 3 days before the CAS procedure and for 90 days after the procedure. They will receive a daily dose of 100 mg aspirin or 75 mg clopidogrel thereafter. For the CAS procedure, local anaesthesia and predilation prior to stent placement are recommended. Use of an embolic protection device is mandatory for all patients who undergo CAS.
Study: NCT02390349

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curamin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CuraMed
Study: NCT00325130

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Adacel™
Description: A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1
Study: NCT04124094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product (Fluticasone propionate and salmeterol xinafoate inhalation powder/Respirent Pharmaceuticals)
Description: Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals
Study: NCT01721291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SALBUTAMOL
Description: In the LUNG DEPOSITION STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT SLOW INHLATION AND AGAIN AT FAST INHALTION;DOSAGE- 30 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION.~In the LUNG PHYSIOLOGY STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT TWO DOSAGES OF 30 MICROGRAMS AND AGAIN AT 15 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION. ALL INHALATIONS WIL BE AT SLOW INHALTION IN THIS PART OF THE STUDY.
Study: NCT01146548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLUOXETINE
Description: 20mg/d, oral administration for 6 weeks, then 40mg/d for 4 months.
Study: NCT03136042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy techniques
Description: oscillating positive expiratory pressure during nonstop 5 minutes. After that more five minutes to a forced expiratory technique

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hypertonic saline 3%
Description: four nebulizations with 3% hypertonic saline, the aerosol was generated by an ultrasonic nebulizer
Study: NCT04124094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Product (SERETIDE DISKUS® 100/50 inhalation powder/GSK)
Description: 2 inhalations in one study period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activated Charcoal suspension
Description: oral suspension before and after inhalation of study Investigational Products

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Activated Charcoal suspension
Description: oral suspension before and after inhalation of study Investigational Products